公开(公告)号：US20140017233A1

公开(公告)日：2014-01-16

申请号：US13836535

申请日：2013-03-15

Applicant: Genentech, Inc.

Inventor： Carlos BAIS ,  Matthew Brauer ,  Mallika Singh ,  Maike Schmidt

IPC: C12Q1/68 ,  A61K45/06 ,  A61K39/395

CPC classification number: C12Q1/6886 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/475 ,  G01N2800/52

Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract translation: 本发明提供了检测一种或多种生物标志物的表达的方法和组合物，用于鉴定和治疗可能对VEGF拮抗剂治疗有反应的患者。 本发明还提供用于该方法的试剂盒和制品。

公开(公告)号：US20150064178A1

公开(公告)日：2015-03-05

申请号：US14471734

申请日：2014-08-28

Applicant: Genentech, Inc.

Inventor： Carlos BAIS ,  Richard Bourgon ,  Heidi Phillips ,  Thomas Sandmann

IPC: C12Q1/68 ,  A61K39/395 ,  A61K45/06 ,  C07K16/22

CPC classification number: A61K45/06 ,  A61K39/39558 ,  C07K16/22 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N2800/52 ,  A61K2300/00

Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract translation: 本发明提供检测一种或多种生物标志物的表达的方法和组合物，用于鉴定和治疗可能对VEGF拮抗剂治疗有反应的成胶质细胞瘤的患者。 本发明还提供用于该方法的试剂盒和制品。

公开(公告)号：US20170226198A1

公开(公告)日：2017-08-10

申请号：US15581448

申请日：2017-04-28

Applicant: Genentech, Inc.

Inventor： Yuanyuan XIAO ,  Carlos BAIS ,  YounJeong CHOI ,  Nicola C. CONSALVO

IPC: C07K16/22 ,  A61K39/395 ,  G01N33/574 ,  A61K31/495 ,  A61K38/21 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/22 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/495 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K38/21 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/76 ,  G01N33/57449 ,  G01N2333/70596 ,  G01N2333/71 ,  G01N2800/52 ,  A61K2300/00

Abstract: The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.

公开(公告)号：US20170051360A1

公开(公告)日：2017-02-23

申请号：US15346164

申请日：2016-11-08

Applicant: Genentech, Inc.

Inventor： Carlos BAIS ,  Richard BOURGON ,  Thomas SANDMANN

IPC: C12Q1/68 ,  A61K45/06 ,  A61K31/4188 ,  C07K16/22 ,  A61K39/395

CPC classification number: C12Q1/6886 ,  A61K31/4188 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract translation: 本发明提供检测一种或多种生物标志物的表达的方法和组合物，用于鉴定和治疗可能对VEGF拮抗剂治疗有反应的成胶质细胞瘤的患者。 本发明还提供用于该方法的试剂盒和制品。

公开(公告)号：US20150065781A1

公开(公告)日：2015-03-05

申请号：US14470443

申请日：2014-08-27

Applicant: Genentech, Inc.

Inventor： Carlos BAIS ,  Richard Bourgon ,  Heidi Phillips ,  Thomas Sandmann

IPC: A61K39/395 ,  A61K31/495

CPC classification number: A61K39/3955 ,  A61K31/495 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  A61K2300/00

Abstract: This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.